North America Endothelial Dysfunction Market Forecast to 2028 - Regional Analysis - by Cause (Hypertension, Diabetes, Hypercholestrolaemia, Bechet’s Disease, Obesity, and Others), Test Type [Invasive Tests and Non-Invasive Tests (Flow Mediated Dilatory, P

North America Endothelial Dysfunction Market Forecast to 2028 - Regional Analysis - by Cause (Hypertension, Diabetes, Hypercholestrolaemia, Bechet’s Disease, Obesity, and Others), Test Type [Invasive Tests and Non-Invasive Tests (Flow Mediated Dilatory, Peripheral Arterial Tonometry (PAT), Venous Occlusion Pletismography, Circulating Markers, and Others)], and End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others)

The North America endothelial dysfunction market is expected to grow from US$ 951.83 million in 2022 to US$ 1,247.30 million by 2028. It is estimated to grow at a CAGR of 4.6% from 2022 to 2028.

Increasing Incidences of Cardiovascular Diseases Fuels North America Endothelial Dysfunction Market

According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are among the leading causes of death worldwide, and ~30 million people experience a stroke each year. CVDs include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and coronary artery disease (CAD). CAD is the most common disease among all cardiovascular diseases, and it is characterized by the accumulation of lipids and immune cells in the subendothelial space of the coronary arteries or atherosclerosis. It involves the inflammatory response of the vascular endothelium. CAD is characterized by ischemia, hypoxia, or necrosis of the myocardium resulting from narrowing, spasm, or obstruction of the coronary artery lumen by atherosclerosis. It has become the leading cause of death worldwide. According to the Centers for Disease Control and Prevention (CDC), over 60 million women (44%) in the US suffer from some form of heart disease. Heart disease is the leading cause of death among women in the US and can affect women of any age. In 2021, it caused 310,661 deaths among women, i.e., nearly one in five female deaths.

According to the American Heart Association, almost half of all adults in the US suffer from a type of CVD. Over 130 million people, i.e., 45.1% of the US population, are projected to suffer from a type of CVD by 2035. Therefore, the high prevalence of cardiovascular diseases due to endothelial dysfunction drives the market.

North America Endothelial Dysfunction Market Overview

The North American endothelial dysfunction market is analyzed on the basis of three major countries: the US, Canada, and Mexico. The market expansion in the region can be attributed to an increase in the incidence of cardiac diseases and rising investments in cardiology informatics. The US holds the largest size of the endothelial dysfunction market in North America owing to factors such as the increasing burden of CAD, established healthcare infrastructure, and R&D activities undertaken to develop advanced endothelial dysfunction drugs and devices.

North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)

North America Endothelial Dysfunction Market Segmentation

The North America endothelial dysfunction market is segmented into cause, test type, end user, and country.

Based on cause, the North America endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment registered the largest North America endothelial dysfunction market share in 2022.

Based on test type, the North America endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger North America endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.

Based on end user, the North America endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest North America endothelial dysfunction market share in 2022.

Based on country, the North America endothelial dysfunction market is segmented into the US, Canada, and Mexico. The US dominated the North America endothelial dysfunction market in 2022.

ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America endothelial dysfunction market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America endothelial dysfunction market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the endothelial dysfunction market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution